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Daniel B. Kramer, MD, MPH; Susan L. Mitchell, MD, MPH; Joao Monteiro, PhD; Paul W. Jones, MS; Sharon-Lise Normand, PhD;
David L. Hayes, MD; Matthew R. Reynolds, MD, MSc
Background-—Physical activity data are collected automatically by implantable cardioverter-deﬁbrillators (ICDs). Though these data
potentially provide a quantiﬁable and easily accessible measure of functional status, its relationship with survival has not been well
studied.
Methods and Results-—Patients enrolled in the Boston Scientiﬁc LATITUDE remote monitoring system from 2008 to 2012 with
ICDs were eligible. Remote monitoring data were used to calculate mean daily activity at baseline (30 to 60 days after
implantation), and longitudinally. Cox regression was used to examine the association between survival and increments of
30 minutes/day in both (1) mean baseline activity and (2) time-varying activity, with both adjusted for demographic and device
characteristics. A total of 98 437 patients were followed for a median of 2.2 years (mean age of 67.713.1 years; 71.7% male).
Mean baseline daily activity was 107.566.2 minutes/day. The proportion of patients surviving after 4 years was signiﬁcantly
higher among those in the most versus least active quintile of mean baseline activity (90.5% vs. 50.0%; log-rank P value, <0.001).
Lower mean baseline activity (i.e., incremental difference of 30-minutes/day) was independently associated with a higher risk of
death (adjusted hazard ratio [AHR], 1.44; 95% conﬁdence interval [CI], 1.427 to 1.462). Time-varying activity was similarly
associated with a higher risk of death (AHR, 1.48; 95% CI, 1.451 to 1.508), indicating that a patient having 30 minutes per day less
activity in a given month has a 48% increased hazard for death when compared to a similar patient in the same month.
Conclusions-—Patient activity measured by ICDs strongly correlates with survival following ICD implantation. ( J Am Heart Assoc.
2015;4:e001775 doi: 10.1161/JAHA.115.001775)
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Implantable cardioverter-deﬁbrillator (ICD) therapy provideslife-saving treatment for patients at high risk for sudden
cardiac arrest.1 However, despite advancements in medical
therapy and device programming, many patients remain at
high risk for short-term death despite ICD implantation.2,3
Predicting which patients are at highest risk for adverse
clinical outcomes has important implications for clinical
management and the design of interventions aimed at
reducing morbidity and mortality following ICD implantation.
Several existing risk models leverage patient clinical charac-
teristics to predict short-term survival in ICD patients.2–4
Though this work has demonstrated an increasing risk for
death with accumulated comorbidity, calculating risk scores
at the bedside may be laborious, and no model has an
established role in either clinical practice or research.5
Patient physical activity information is collected automati-
cally by many ICDs. These activity data provide a quantitative,
easily accessible measure that may reﬂect individual functional
status.6,7 Previous studies evaluating patient activity alone6 or
integrated with other diagnostics8 in heart failure (HF) patients
with ICDs suggest an inverse relationship with survival,
adjusted for other clinical factors. However, these studies were
relatively small, did not evaluate patients without HF, and
provided only limited descriptions of activity patterns over time.
Thus, the aims of this study were to investigate the
distribution of patient activity following ICD implantation and
the relationship between patient activity and survival. Specif-
ically, we analyzed a large, nation-wide database of ICD
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recipients to evaluate survival according to patient activity at
baseline, measured shortly after implantation, and longitudi-
nally using a time-varying analytic approach.
Methods
Data Source
The ALTITUDE registry was established in 2008 to prospec-
tively analyze data from ICD and cardiac resynchronization
therapy (CRT-D) devices followed through the LATITUDE
clinical remote monitoring system (Boston Scientiﬁc Corp,
Natick, MA). LATITUDE earned U.S. Food and Drug Adminis-
tration approval in 2005, and since 2006, all new Boston
Scientiﬁc ICD and CRT-D implants have been eligible for
enrollment in this remote follow-up network. The remote
system consists of a base station capable of device interro-
gation and transmission that is placed in the patient’s home.
These interrogations may be patient initiated or (for some
models) performed automatically by wireless telemetry. Data
are then transferred by telephone line and are accessible for
routine clinical care through a secure website administered by
Boston Scientiﬁc. The decision to enroll a patient in the
remote follow-up system is made by the implanting physician
at the time of device implantation or at routine postimplan-
tation follow-up clinic visits.
Deidentiﬁed data from the LATITUDE network forms the
data set for ALTITUDE studies. Investigator-initiated proposals
to ALTITUDE are reviewed by an independent physician
leadership panel and projects with sufﬁcient scientiﬁc merit
are supported. Several previous studies have successfully
queried the ALTITUDE database to assess arrhythmic events
and survival.9–11
This project was additionally reviewed by the Hebrew
SeniorLife Institute for Aging Research Institutional Review
Board (Boston, MA).
Study Population
Patients receiving new or replacement ICD or CRT-D devices
from January 1, 2008 to December 31, 2012 who were
entered into the LATITUDE network were eligible for inclusion.
This entry date was chosen to coincide with introduction of an
ICD software platform that supported daily recording and
upload of patient activity. Study follow-up ended on March 1,
2013 to allow collection of baseline activity information for all
included subjects, while also providing sufﬁcient lag time for
reporting of deaths into the national death index (NDI).
Patients without a compatible ICD platform, missing demo-
graphic information (including Social Security numbers), or
without usable patient activity data were excluded from
analysis (see Figure 1). The majority of exclusions owing to
unusable activity data arose from patients in whom a
truncated transmission to LATITUDE resulted in loss of
historical activity information.
Patient Activity
Patient activity in Boston Scientiﬁc devices is measured
through an integrated circuit accelerometer embedded in the
pulse generator itself, which, in applicable patients, can also
be used for rate-responsive pacing. The accelerometer
detects both the frequency and amplitude of patient motion
and translates this into a proportional electrical signal. A
proprietary algorithm interprets this signal and speciﬁes
whether the sensor exceeds a threshold of 25 milligravities,
corresponding to an approximate walking speed of 2 miles/h,
in order to determine a state of “active” or “not active” for a
given minute. The sensor maintains a log of the percent of
time a patient is considered active or not active for each daily
24-hour period. The device models marketed during the study
period are capable of storing up to 1 year of daily patient
activity data. At each LATITUDE upload, all available activity
data are uploaded. Thus, for our analysis, complete patient
Figure 1. Study ﬂow with derivation of the study population.
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activity data were available for each patient with at least 1
upload per 12-month rolling period.
We deﬁned “baseline” patient activity as the mean
minutes/day considered active for the period 30 to 60 days
after device implant. This time period was selected a priori to
account for clinical procedural recovery and the expected
short delay between implant and successful enrollment in
LATITUDE. In addition, longitudinal daily patient activity was
recorded from day 60 through the date of the patient’s last
upload to LATITUDE.
Survival
Vital status and, when applicable, date of death were drawn
from the Boston Scientiﬁc Data Tracking database, which
monitors patient clinical status through 2 complementary
means. First, linkage to the NDI allows for rolling updates of
patient vital status. For our study, we selected March 1, 2013
as our last follow-up date to allow for a potential lag in
reporting. In addition, deaths reported to Boston Scientiﬁc as
part of routine patient care are included on the Boston
Scientiﬁc Tracking database records. Patient follow-up was
censored at the date of death, the last LATITUDE transmis-
sion, or end of study.
Other Variables
The ALTITUDE registry provides selected demographic vari-
ables, including age at implant and sex. Procedural and
device-speciﬁc variables collected included the date of
implant; single-chamber, dual-chamber, or CRT-D device;
and previous ICD implant.
Statistical Analysis
All baseline demographic data, clinical information, and
procedural variables were described using frequencies for
categorical variables and means/medians with SDs/inter-
quartile ranges for continuous variables. For baseline patient
activity, we ﬁrst identiﬁed the meanSD minutes/day active
during the 30- to 60-day period for the entire population.
Next, we divided the cohort into quintiles of baseline activity
and summarized activity levels as well as baseline character-
istics for each quintile. Patient characteristics across quintiles
were compared using ANOVA for continuous variables or chi-
square test for categorical variables.
Unadjusted survival for the overall cohort and each quintile
was evaluated with the Kaplan-Meier method, with calculation
of hazard ratios (HRs) and 95% conﬁdence intervals (CIs) using
the log-rank test for association between quintile and survival
with 4 df. To further evaluate the relationship between patient
activity and survival, we used Cox regression and considered
baseline patient activity as a continuous variable, with an
incremental change of 30 minutes/day considered the unit of
analysis. This model included age, gender, device type, previous
ICD implant, and minutes/day of activity, yielding an adjusted
hazard ratio (AHR) with 95% CI.
For our longitudinal analysis, we considered activity as a
time-varying variable, which allows for each subject to have
separate evaluable activity measurements for each time point
of follow-up. This approach is commonly used for variables
expected to vary over time, such as blood pressure. We ﬁrst
evaluated the calculated mean  SD of monthly patient
activity, which describes interpersonal variability over time.
We also calculated the meanSD of the SD of activity over
time, which provides a measure of intrapersonal variability
over time. Last, we repeated the Cox regression model using
mean patient activity in each 30-day period (30 minutes/day
incremental change) as a time-varying variable, adjusting for
age, sex, device type (CRT vs. non-CRT), and previous ICD,
yielding HRs and 95% CIs for each covariate.
Results
Baseline Characteristics
From 132 745 patients implanted with Boston Scientiﬁc ICDs
and enrolled in LATITUDE during the study period, 98 437
were eligible for analysis (Figure 1). Median follow-up time for
the ﬁnal cohort was 2.2 years. Demographic and device-
based characteristics of the overall cohort and stratiﬁed by
quintile of activity level are shown in Table 1. Overall, patients
had a mean age of 67.713.1 years and 71.7% were male,
with 43.4% and 56.6% receiving CRT or ICD (single- or dual-
chamber) devices, respectively, and 30.5% having had an ICD
previously.
Baseline physical activity for the entire cohort in the 30- to 60-
day window post-ICD implantation averaged 107.566.2 min-
utes/day, ranging from a mean of 32.513.5 minutes/day in
the lowest quintile to 207.758.5 minutes/day in the most
active quintile (Table 1; P<0.0001, by ANOVA for trend across
quintiles). Compared with themost active quintile, patients in the
least active quintile tended to be older (mean age 74.610.3 vs.
59.314.0 years), female (35.6% vs. 21.1%), and more com-
monly received a CRT device (53.2% vs. 30.4%), compared to
patients in the most active quintile (Table 1; P<0.0001, for trend
across quintile groups for all characteristics).
Association Between Baseline Activity and
Survival
Estimated survival by the Kaplan-Meier method for the entire
cohort at 1 and 4 years were 95.0% and 76.1%, respectively
(Table 2, Figure 2). In unadjusted analyses, baseline activity
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by quintile was strongly associated with survival. At 1 year
post-ICD implant, the most active quintile demonstrated
survival of 98.7% versus 86.5% for the least active (P<0.001).
The proportion of patients surviving after 4 years was
strikingly higher among those in the highest (most active)
versus lowest (least active) quintile of mean baseline activity
(90.5% vs. 50.0%; P value, <0.001). After adjustment for age,
gender, CRT versus non-CRT device, and de novo versus
replacement ICD, lower mean baseline activity (i.e., incre-
mental difference of 30 minutes/day) was independently
associated with a higher risk of death (AHR, 1.44; 95% CI,
1.427 to 1.462).
Time-Varying Analysis
During the study follow-up period, an average of 720.3436.3
daily measurements were collected from each patient at a
median of 2.2 years of follow-up. As expected, the number of
patients with observed daily activity measurements and total
number of activity measurements/patient declined proportion-
ally with time. However, for each month of follow-up, patients
contributed, on average, nearly 30 days of measurements.
Over time, mean patient activity was 111.066.1 minutes/
day, similar to the 107.566.2 for the baseline period. In terms
of within-patient variability, mean SD of activity was
37.221.0 minutes/day, indicating that, 95% of the time,
any given patient’s daily activity ranged 79.2 minutes from
his or her mean daily activity.
Time-varying patient activity predicted survival in a
multivariate Cox regression model including age, sex, device
type, and previous ICD alongside each patient’s activity in any
given 30-day period. The AHR of 1.479 (95% CI, 1.451 to
1.508; Table 3) indicates that a patient having 30 minutes
per day less activity in a given month had a 48% increased
hazard for death, when compared to a similar patient in the
same month.
Discussion
This study presents, to our knowledge, the largest evaluation
of patient activity in ICD patients. The principal ﬁnding is that
device-detected activity is strongly correlated with survival
after adjustment for age, sex, and device type. Patient
physical activity considered in just the ﬁrst 30 to 60 days
after implantation yielded a 40% absolute difference in survival
at 4 years between the most and least active quintiles (90.8%
vs. 50.0%). This marked inverse relationship between activity
and mortality was similar regardless of whether baseline
activity or longitudinal activity is considered, with a similarly
increased hazard for death for incremental difference of
activity of only 30 minutes after adjustment for demographic
and clinical covariates.
This study builds upon previous work evaluating patient
activity in patients with ICDs, particularly those with HF. For
example, Conraads et al.6 evaluated 781 HF patients
blended from the SENSE-HF and DOT-HF studies, both of
which enrolled patients with chronic systolic HF despite
optimal medical therapy. “Early patient activity,” deﬁned as
average activity in the earliest available 30-day window,
predicted survival at a mean follow-up of 157 months, with
an HR of 0.93 for each 10 minutes/day of activity after
adjustment for several clinical variables. In this study, adding
activity to the CHARM risk model for HF signiﬁcant improved
risk stratiﬁcation. These data complement work from
Whellan et al.8 from the PARTNERS-HF study, in which
694 patients with CRT-D implants were evaluated using a
diagnostic algorithm combining low patient activity
(<1 hour/day) with atrial ﬁbrillation duration and ventricular
response, ICD shocks, nighttime heart rate, heart rate
variability, transthoracic impedance, and percent of CRT
pacing. At 11.72 months of follow-up, patients whose
algorithms met prespeciﬁed thresholds were 5.5 times as
likely to experience an HF hospitalization, though the
Table 1. Demographic and Clinical Characteristics of the Entire Study Population and Stratiﬁed By Quintile of Baseline Physical
Activity
Characteristic
Entire Study
(N=98 437)
Quintile 1
(N=19 693)
Quintile 2
(N=19 691)
Quintile 3
(N=19 674)
Quintile 4
(N=19 692)
Quintile 5
(N=19 687) P Value**
Mean baseline activity,
minutes/day*
107.566.2 32.513.5 67.68.6 97.38.9 132.512.0 207.758.5 <0.0001
Age, meanSD 67.713.1 74.610.3 71.610.9 68.411.7 64.612.5 59.314.0 <0.0001
Male (%) 70 533 (71.7) 12 675 (64.4) 13 649 (69.3) 14 038 (71.4) 14 629 (74.3) 15 542 (78.9) <0.0001
CRT device (%) 42 675 (43.4) 10 480 (53.2) 9786 (49.7) 8793 (44.7) 7630 (38.7) 5986 (30.4) <0.0001
Previous ICD implant (%) 30 005 (32.5 6926 (35.2) 6129 (31.1) 5961 (30.3) 5618 (28.5) 5371 (27.3) <0.0001
CRT indicates cardiac resynchronization therapy; ICD, implantable cardioverter-deﬁbrillator.
*Mean minutes/day active in the ﬁrst 30 to 60 days post-ICD implantation).
**P value for comparison across quintiles by ANOVA.
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performance of patient activity alone was not reported. A
follow-up study from Cowie et al.12 validating a “heart failure
score” using a similar suite of variables in 1310 patients
(including those from the PARTNERS-HF study) identiﬁed
2.5-fold increase in the risk for an HF hospitalization in the
next 30 days for patients with low activity alone. Our study
thus supports and solidiﬁes a growing body of literature on
the use of activity alone or alongside other diagnostic
parameters to identify ICD patients at high risk for adverse
clinical events.
Our results raise questions about the underlying mecha-
nisms and associations of patient activity. Presumably,
patients with better overall health would be expected both
to live longer and be more active, and we cannot evaluate
causality in our study design. However, relatively few data
describe speciﬁc correlates of activity in ICD populations.
Conraads et al.6 identiﬁed age, HF severity, peripheral and
ischemic arterial disease, and atrial ﬁbrillation to be predic-
tors of patient activity, though the strong relationship with
survival persisted after adjustment for these factors.6 Notably,
however, this study excluded patients with chronic obstruc-
tive lung disease, pulmonary hypertension, and those under-
going hemodialysis, comorbidities potentially relevant for a
signiﬁcant proportion of ICD recipients.3,13
Similarly, Vegh et al. evaluated physical activity and 6-
minute walk tests in a single-center study of 164 CRT
patients, ﬁnding both to predict HF hospitalizations with
similar HRs after adjustment for clinical factors and medica-
tion use.14 Interestingly, though, the correlation between
activity and the 6-minute walk was only modest. Kadhiresan
et al.7 evaluated patient activity as well as 6-minute walk
tests in 30 patients receiving CRT devices and found activity
to be 84% sensitive and 73% speciﬁc for changes in distance
walked. Thus, a more complete understanding of the compo-
nents of activity in ICD patients will require further investi-
gation. In particular, the activity measurements from the ICDs
used in our study have not, to our knowledge, been validated
against other accepted measures of activity, such as omni-
directional accelerometry.
In addition to a need for external validation of our
activity measure, the principal limitation of our analysis is
the lack of clinical covariates for inclusion in our modeling
of survival. Though other work in this area has found that
Figure 2. Survival and number of patients at risk for entire
study population and stratiﬁed by quintile of patient baseline daily
activity.
Table 2. Survival for Entire Study Cohort and Stratiﬁed by Quintile of Mean Minutes/Day Active in the First 30 to 60 Days After
Implantable Cardioverter-Deﬁbrillator Implantation
Survival
Outcomes
Mean Baseline Activity (Minutes/Day)
P Value*
Entire Study
(N=98 437)
107.566.2
Quintile 1
(N=19 693)
32.513.5
Quintile 2
(N=19 691)
67.68.6
Quintile 3
(N=19 674)
97.38.9
Quintile 4
(N=19 692)
132.512.0
Quintile 5
(N=19 687)
207.758.5
Survival at
1 year
(95% CI)
0.950
(0.948 to 0.951)
0.865
(0.860 to 0.870)
0.945
(0.942 to 0.948)
0.968
(0.965 to 0.970)
0.982
(0.980 to 0.984)
0.987
(0.986 to 0.989)
<0.0001
Survival at
2 years
(95% CI)
0.882
(0.879 to 0.884
0.713
(0.705 to 0.720)
0.858
(0.852 to 0.863)
0.916
(0.911 to 0.920)
0.947
(0.943 to 0.950)
0.965
(0.962 to 0.968)
<0.0001
Survival at
3 years
(95% CI)
0.818
(0.815 to 0.821)
0.593
(0.584 to 0.602)
0.774
(0.767 to 0.782)
0.855
(0.848 to 0.861)
0.906
(0.901 to 0.911)
0.939
(0.935 to 0.943)
<0.0001
Survival at
4 years
(95% CI)
0.761
(0.757 to 0.765)
0.500
(0.488 to 0.512)
0.704
(0.694 to 0.715)
0.794
(0.785 to 0.804)
0.865
(0.857 to 0.873)
0.908
(0.901 to 0.914)
<0.0001
CI indicates conﬁdence interval.
*P value for trend across quintiles according to log-rank test.
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activity remains important after adjustment for HF severity
and other comorbidities, our study design did not allow for
a comparable statistical model. In addition, our data source
only included patients from a single manufacturer’s ICDs,
as well as those who elected to participate in remote
monitoring. Whether these results extend to other brands
of ICDs, whose algorithms for measuring activity may differ,
remains unknown. Again, measurement of patient activity
by pectoral accelerometer may be insensitive to speciﬁc
types of exercise, such as stationary bicycling or swimming,
and of uncertain validity compared with other measure-
ments of activity.15 However, the relatively low threshold
for identifying a time period as active would argue that
subjects regularly engaged in biking or swimming would
likely be identiﬁed as comparatively active in daily life
otherwise. Our survival analysis depended on identiﬁcation
of vital status using the Social Security Death Index, which
may result in under-reporting of deaths, though we selected
the endpoint for our follow-up period to account for a lag in
reporting. Our analysis could not identify cause of death,
which further emphasizes the need to more clearly explore
the mechanisms through which patient activity predicts
survival. In particular, whether activity in a broadly selected
ICD population distinguishes sudden and nonsudden deaths
remains uncertain, and, in either case, we again note that
the association we have identiﬁed does not imply a causal
relationship. Indeed, though we were able to clearly risk
stratify patients for death according to activity, without a
non-ICD control group we cannot comment on whether
protection from arrhythmic death speciﬁcally beneﬁted
different quintiles of activity differentially.
Despite these limitations, there may be clinical and
research opportunities for utilizing activity information
gleaned from ICDs, which, unlike more-complex risk models,
is readily available. If further validated, our ﬁndings suggest
that evaluating activity in an ICD patient before undergoing an
ICD replacement procedure may provide additional prognostic
information. Decisions around ICD replacement remain
controversial and plagued by relatively scarce data regarding
outcomes, compared with new ICD implantation.13,16,17 For
patients and clinicians uncertain about expected survival with
an ICD, patient activity provides a simple risk discriminator
that—in our study of >225 000 patient-years of follow-up—
starkly separated outcomes for high- and low-activity individ-
uals. Again, though survival without an ICD in these
subpopulations is unknown, patient and physician expecta-
tions about survival with a device may support shared
decision making.18,19 Use of device-adjudicated activity levels
to measure patient response to, for example, CRT implanta-
tion or optimization, may also provide a simple, quantitative
assessment of functional response more rigorous and
granular than New York Heart Association class and simpler
than typical patient-reported outcome scales.
In sum, we observe, in a nation-wide sample of ICD
patients, a striking relationship between both early and time-
varying activity and survival. Future work, including external
validation of the activity measurement, may expand our
understanding of the components of activity itself while
clarifying the causal relationship and mechanisms underlying
this association.
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